Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Zenas BioPharma (ZBIO) EBIT Margin (2023 - 2025)

Zenas BioPharma (ZBIO) has 2 years of EBIT Margin data on record, last reported at 373.3% in Q1 2025.

  • For Q1 2025, EBIT Margin changed N/A year-over-year to 373.3%; the TTM value through Sep 2025 reached 1337.97%, changed N/A, while the annual FY2024 figure was 3277.76%, 320347.0% down from the prior year.
  • EBIT Margin reached 373.3% in Q1 2025 per ZBIO's latest filing, up from 1112.46% in the prior quarter.
  • Across five years, EBIT Margin topped out at 373.3% in Q1 2025 and bottomed at 1112.46% in Q4 2024.